Terms: = Skin cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Clinical Outcome
14 results:
1. ptenP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Suryo Rahmanto A; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Frostvik Stolt M; Tuominen R; Sangfelt O; Pokrovskaja Tamm K; Hansson J; Grandér D; Egyházi Brage S; Johnsson P
Sci Rep; 2021 May; 11(1):11023. PubMed ID: 34040017
[TBL] [Abstract] [Full Text] [Related]
2. Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome.
Kenawy N; Kalirai H; Sacco JJ; Lake SL; Heegaard S; Larsen AC; Finger PT; Milman T; Chin K; Mosci C; Lanza F; Moulin A; Schmitt CA; Caujolle JP; Maschi C; Marinkovic M; Taktak AF; Heimann H; Damato BE; Coupland SE
Pigment Cell Melanoma Res; 2019 Jul; 32(4):564-575. PubMed ID: 30672666
[TBL] [Abstract] [Full Text] [Related]
3. Revisiting the clinical and Biologic Relevance of Partial pten Loss in Melanoma.
Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
[TBL] [Abstract] [Full Text] [Related]
4. Activated MEK cooperates with Cdkn2a and pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract] [Full Text] [Related]
5. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract] [Full Text] [Related]
6. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract] [Full Text] [Related]
7. Atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): case series, immunohistochemical profile and review of the literature.
Hall BJ; Grossmann AH; Webber NP; Ward RA; Tripp SR; Rosenthal HG; Florell SR; Randall RL; Cockerell CJ; Layfield LJ; Liu T
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):132-8. PubMed ID: 22820664
[TBL] [Abstract] [Full Text] [Related]
8. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
[TBL] [Abstract] [Full Text] [Related]
9. The biology and management of uveal melanoma.
Sato T; Han F; Yamamoto A
Curr Oncol Rep; 2008 Sep; 10(5):431-8. PubMed ID: 18706273
[TBL] [Abstract] [Full Text] [Related]
10. Integrative genomic analysis of aneuploidy in uveal melanoma.
Ehlers JP; Worley L; Onken MD; Harbour JW
Clin Cancer Res; 2008 Jan; 14(1):115-22. PubMed ID: 18172260
[TBL] [Abstract] [Full Text] [Related]
11. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Jönsson G; Dahl C; Staaf J; Sandberg T; Bendahl PO; Ringnér M; Guldberg P; Borg A
Oncogene; 2007 Jul; 26(32):4738-48. PubMed ID: 17260012
[TBL] [Abstract] [Full Text] [Related]
12. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of pten in uveal melanoma.
Abdel-Rahman MH; Yang Y; Zhou XP; Craig EL; Davidorf FH; Eng C
J Clin Oncol; 2006 Jan; 24(2):288-95. PubMed ID: 16344319
[TBL] [Abstract] [Full Text] [Related]
13. Expression of activated Akt and pten in malignant melanomas: relationship with clinical outcome.
Slipicevic A; Holm R; Nguyen MT; Bøhler PJ; Davidson B; Flørenes VA
Am J Clin Pathol; 2005 Oct; 124(4):528-36. PubMed ID: 16146807
[TBL] [Abstract] [Full Text] [Related]
14. Severe Lhermitte-Duclos disease with unique germline mutation of pten.
Sutphen R; Diamond TM; Minton SE; Peacocke M; Tsou HC; Root AW
Am J Med Genet; 1999 Feb; 82(4):290-3. PubMed ID: 10051160
[TBL] [Abstract] [Full Text] [Related]
